A Phase II Clinical Trial of Topotecan in Japanese Patients with Relapsed Ovarian Carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A Phase II Clinical Trial of Topotecan in Japanese Patients with Relapsed Ovarian Carcinoma

Published:2010-10-25 Issue:3 Volume:41 Page:320-327
ISSN:0368-2811
Container-title:Japanese Journal of Clinical Oncology
language:en
Short-container-title:Japanese Journal of Clinical Oncology

Author:

Aoki D.,Katsumata N.,Nakanishi T.,Kigawa J.,Fujiwara K.,Takehara K.,Kamiura S.,Hiura M.,Hatae M.,Sugiyama T.,Ochiai K.,Noda K.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://academic.oup.com/jjco/article-pdf/41/3/320/5102467/hyq192.pdf

Reference10 articles.

1. Topotecan: A New Topoisomerase I Inhibiting Antineoplastic Agent

2. Equilibrium kinetics of the new experimental anti-tumour compound SK&F 104864-A in aqueous solution

3. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma.

4. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study.

5. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A ciprofloxacin derivative with four mechanisms of action overcomes paclitaxel resistance in p53-mutant and MDR1 gene-expressing type II human endometrial cancer;Biomaterials;2023-05

2. A phase II study of irinotecan and pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study);Cancer Chemotherapy and Pharmacology;2017-06-27

3. A phase I study of irinotecan and pegylated liposomal doxorubicin in recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study);Cancer Chemotherapy and Pharmacology;2014-03-01

4. The chemotherapeutic agent topotecan differentially modulates the phenotype and function of dendritic cells;Cancer Immunology, Immunotherapy;2013-05-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3